Trials / Completed
CompletedNCT01678755
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Smokers
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 157 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 20 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This is an efficacy study evaluating a experimental treatment for cognitive deficits in adults with schizophrenia.
Detailed description
Safety and Efficacy Study for Cognitive Deficits in Adult Subjects with Schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-126 | ABT-126 Low Dose |
| DRUG | ABT-126 | ABT-126 High Dose |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2014-03-01
- Completion
- 2014-03-01
- First posted
- 2012-09-05
- Last updated
- 2021-07-07
Locations
20 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01678755. Inclusion in this directory is not an endorsement.